Topic: outsourcing

Medpace Corporate Headquarters

Cinven swoops in to buy control of CRO Medpace for $915M

The private equity group announced this morning that it will buy out Medpace, continuing an M&A trend that has spurred a sizable shakeout of the CRO business in recent years. With outsourcing growing increasingly popular in the biopharma industry, the financiers are finding some significant upside in buying--and then selling--CROs.